A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T-Cell Lymphoma (TCL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Cleveland Clinic

Protocol Number
CASE1415

To Learn More Call
(201)-510-0950